Company Information

  

Address: 24 WEST 40TH STREET
8TH FLOOR 
City: NEW YORK 
State: NY 
Zip Code: 10018 
Telephone: (646) 350-0702 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

Our legal and commercial name is Akari Therapeutics, PLC. We were originally established as a private limited company under the laws of England and Wales on October 7, 2004 under the name Freshname No. 333 Limited. On January 19, 2005, we changed our name to Morria Biopharmaceuticals Limited and on February 3, 2005, we completed a reverse merger with Morria Biopharmaceuticals Inc., or Morria, a Delaware corporation, in which Morria became our wholly-owned subsidiary and we re-registered as a non-traded public limited company under the laws of England and Wales. Morria was dedicated to the discovery and development of novel, first-in-class, non-steroidal, synthetic anti-inflammatory drugs. On March 22, 2011, we incorporated an Israeli subsidiary, Morria Biopharma Ltd. On June 25, 2013, we changed our name to Celsus Therapeutics PLC and on October 13, 2013 Morria was renamed Celsus Therapeutics Inc. As of the date of this report, Celsus Therapeutics Inc.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
12/2016-0.02NAN/E
03/2016-0.05NAN/E
12/2015-0.05NAN/E
09/2015-0.40NAN/E
03/2015-34.00NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2016 Leverage 2016
Net Inc/Comm Equity-0.17Total Liab/Total Assets0.26
Net Inc/Total Assets-0.40Total Liab/Inv Cap0.34
Net Inc/Inv Cap-0.53Total Liab/Comm Equity0.11
Pretax Inc/Net SalesNAInterest Coverage RatioNA
Net Inc/Net SalesNACurr Debt/EquityNA
Cash Flow/Net SalesNALTD/EquityNA
SG&A/NetSalesNATotal Debt/EquityNA
Asset Utilization   Liquidity  
Net Receivables TurnoverNAQuick Ratio3.90
Inventory TurnoverNACurrent Ratio3.90
Inventory Day SalesNANet Rec/Curr AssetsNA
Net Sales/Work CapNAInv/Curr AssetsNA
Net Sales/PP&ENA  

Income Statement (Millions)

  12/31/2016 3/31/2016 12/31/2015 9/30/2015
Total Revenues(Net Sales) NA NA NA NA
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 9.94 2.35 24.79 22.47
Operating Income -27.25 -3.85 -30.58 -26.29
Interest Exp 0.00 0.00 26.03 26.03
Pretax Income -18.14 -2.99 -45.32 -51.79
Other Income 9.11 0.87 11.29 0.58
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -18.14 -2.99 -45.32 -51.79

Balance Sheet (Millions)

Assets 12/31/2016 3/31/2016 12/31/2015 9/30/2015
Cash & Short Term Investments 44.12 61.43 68.92 78.77
Receivables - Total 0.00 0.01 0.01 NA
Inventories - Total NA NA NA NA
Total Current Assets 45.63 62.69 69.66 78.94
Net Property, Plant & Equipment 0.06 0.07 0.04 0.03
Total Assets 45.87 62.96 69.89 79.17
Liabilities        
Accounts Payable 4.05 0.86 4.73 10.63
Debt in Current Liabilities NA NA NA NA
Total Current Liabilities 11.71 16.55 21.12 37.80
Long-Term Debt NA NA NA NA
Total Liabilities 11.77 16.60 21.17 37.84
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock NA NA NA NA
Common Stock 18.34 18.34 18.34 18.34
Retained Earnings -74.94 -59.78 -56.80 -63.27
Treasury Stock NA NA NA NA
Total Stockholders' Equity 34.10 46.36 48.72 41.33
Total Liabilities and Stockholders' Equity 45.87 62.96 69.89 79.17

Cash Flow Summary (Millions)

Categories 12/31/2016 3/31/2016 12/31/2015 9/30/2015
Net Cash Provided by Operating Activities -24.62 -7.44 -4.97 1.80
Net Cash Provided by Investing Activities -10.07 -0.04 1.39 1.41
Net Cash Provided by Financing Activities 0.00 NA 69.04 72.10

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20110.00-2.12--
12/20120.00-4.27--
12/20130.00-3.62--
12/20150.00-45.32-0.05
12/20160.00-18.14-0.02
Growth RatesNaN----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/17203,3310.28




Report Date : 10/16/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.